Last €2.36 EUR
Change Today +0.031 / 1.33%
Volume 0.0
AJ81 On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 9:34 AM 10/23/14 All times are local (Market data is delayed by at least 15 minutes).

agenus inc (AJ81) Snapshot

Open
€2.34
Previous Close
€2.33
Day High
€2.36
Day Low
€2.34
52 Week High
03/5/14 - €3.95
52 Week Low
04/17/14 - €1.71
Market Cap
147.9M
Average Volume 10 Days
655.9
EPS TTM
--
Shares Outstanding
62.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AGENUS INC (AJ81)

agenus inc (AJ81) Related Businessweek News

No Related Businessweek News Found

agenus inc (AJ81) Details

Agenus Inc., a biopharmaceutical company, is developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines, and adjuvants. Its proprietary discovery engine Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating full-length IgG format human antibody libraries expressed in mammalian B-lineage cells. The company’s portfolio of checkpoint modulator programs is advancing in preclinical development. Its heat shock protein vaccines for cancer and infectious disease are in Phase II studies. The company’s QS-21 Stimulon adjuvant platform, which is partnered with GlaxoSmithKline and Janssen, includes various candidates in Phase III trials. In addition, it has 23 programs are in clinical development. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

114 Employees
Last Reported Date: 03/7/14
Founded in 1994

agenus inc (AJ81) Top Compensated Officers

Founder, Executive Chairman and Chief Executi...
Total Annual Compensation: $489.7K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $215.7K
Chief Compliance Officer, Vice President, Gen...
Total Annual Compensation: $256.5K
Chief Business Officer
Total Annual Compensation: $183.7K
Compensation as of Fiscal Year 2013.

agenus inc (AJ81) Key Developments

Agenus Seeks Acquisitions

Agenus Inc. (NasdaqCM:AGEN) has filed a shelf registration in the amount of $150.00 million. Agenus said, "We expect to use the net proceeds from the sale of the securities from offerings under this prospectus for general corporate purposes unless the applicable prospectus supplement states otherwise. General corporate purposes may include working capital, capital expenditures, repayment and refinancing of debt, research and development expenditures, clinical trial expenditures, acquisitions of additional companies or technologies and investments."

Agenus Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014

Agenus Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.

Agenus Inc. Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014

Agenus Inc. announced unaudited consolidated financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of $3.074 million against $0.807 million a year ago. Operating loss was $8.220 million against $7.329 million a year ago. Net loss attributable to common stockholders was $7.813 million or $0.12 per diluted share against $11.193 million or $0.40 per diluted share a year ago. For the six months, the company reported revenue of $3.795 million against $1.917 million a year ago. Operating loss was $18.323 million against $11.937 million a year ago. Net loss attributable to common stockholders was $8.501 million or $0.15 per diluted share against $20.035 million or $0.76 per diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AJ81:GR €2.36 EUR +0.031

AJ81 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AJ81.
View Industry Companies
 

Industry Analysis

AJ81

Industry Average

Valuation AJ81 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 38.1x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGENUS INC, please visit www.antigenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.